Skip to main content
. Author manuscript; available in PMC: 2013 Nov 7.
Published in final edited form as: Neuropharmacology. 2009 Feb 5;56(0):10.1016/j.neuropharm.2009.01.020. doi: 10.1016/j.neuropharm.2009.01.020

Figure 12. Effect of the 5-HT1A antagonist WAY 100635 on the activity of PG01037.

Figure 12

Unilaterally lesioned animals were used to test the effect of the 5-HT1A antagonist WAY 100635 on the ability of either buspirone or PG01037 to attenuate L-dopa-dependent abnormal involuntary movements. L-Dopa was administered at a dose of 8 mg/kg by i.p. injection. PG01037 and L-dopa were always administered simultaneously. WAY 100635 was always administered 10 minutes prior to the administration of test compounds (PG01037 or buspirone). Buspirone was administered 30 minutes prior to the administration of L-dopa. Data are presented as the total AIMs score normalized to 100 ± the normalized S.E.M. The conditions of the experiment are as follows: A. L-dopa in the absence of any test compound (vehicle control #1); B. L-dopa in the presence of buspirone (4 mg/kg); C. L-dopa in the presence of both buspirone (4 mg/kg) and WAY 100635 (1 mg/kg); D. L-dopa in the absence of any test compound (vehicle control #2); E. L-dopa in the presence of 3 mg/kg PG01037; F. L-dopa in the presence of both PG01037 (3 mg/kg) and WAY 100634 (1 mg/kg); G. L-dopa in the absence of test compound (vehicle #3); H. L-dopa in the presence of PG01037 (6 mg/kg); I. L-dopa in the presence of both PG01037 (6 mg/kg) and WAY 100634 (1 mg/kg). The administration of WAY 100635 (1 mg/kg) resulted in a 35% reduction in the attenuation of total AIM scores by buspirone (4 mg/kg). The administration of WAY 100635 (1 mg/kg) resulted in no reduction in the attenuation of total AIM scores by PG01037 at a dose of 3 mg/kg. The administration of WAY 100635 (1 mg/kg) resulted in a 15% reduction in the attenuation of total AIM scores by PG01037 at a dose of 6 mg/kg. The asterisk (*) denotes significant difference (p < 0.05) between the effects of a) buspirone versus vehicle control (A vs. B) (p <0.0001) and buspirone with WAY 100635 with the vehicle control (A vs. C) (p < 0.01), b) buspirone in the absence and presence of WAY 100635 (B vs. C) (p = 0.001), c) PG01037 at 6 mg/kg and vehicle (G vs. H) (p < 0.0001) and d) PG01037 and WAY 100635 and the vehicle control (G vs. I) (p =0.001). There was no significant effect of WAY 100635 on PG01037 at either 3 or 6 mg/kg (p > 0.1).